Disease · MONDO_0004963
T-cell acute lymphoblastic leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. T-cell acute lymphoblastic leukemia. Diseases, record MONDO_0004963. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004963
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
T acute lymphoblastic leukaemia, T acute lymphoblastic leukemia, T-ALL, T-cell ALL, T-cell acute lymphoblastic leukaemia, T-cell acute lymphocytic leukemia, T-cell lymphoblastic lymphoma, T-cell type acute leukaemia, T-cell type acute leukemia, acute T cell leukemia, acute T cell lymphoblastic leukaemia, acute T cell lymphoblastic leukemia, acute T cell lymphocytic leukaemia, acute T cell lymphocytic leukemia, acute T-cell leukaemia, precursor T lymphoblastic leukaemia, precursor T-lymphoblastic leukaemia (T-cell ALL), precursor T-lymphoblastic leukemia, precursor T-lymphoblastic leukemia (T-cell ALL)
- Open Targets
Drugs64
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NELARABINE | CHEMBL1201112 | Small molecule | Approval | DailyMed and PMDA | 9 | 6 | 6 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 7 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| MERCAPTOPURINE | CHEMBL1200751 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ASPARAGINASE | CHEMBL2108989 | Enzyme | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 64
See all 64 drugsTargets130
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 8 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 5 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 3 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 5 | Bcr/Abl fusion protein inhibitor | Phase 3 | https://conductscience.org/library/genes/613 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 3 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 3 | Platelet-derived growth factor receptor beta inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 3 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 3 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 3 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 3 | https://conductscience.org/library/genes/5424 | Drugs and targets |
1 to 10 of 130
See all 130 targetsTrials35
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00878189 | A Trial In Patients With Advanced Cancer And Leukemia | Phase 1 | 72 | 2019-11-12 | Neoplasms by Histologic Type | NIROGACESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1/2 | 23 | 2020-10-01 | Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma | CYCLOPHOSPHAMIDE, ETOPOSIDE, NELARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT02999633 | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | Phase 2 | 14 | 2020-01-18 | T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia | ISATUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01274533 | Lenalidomide in HTLV-1 Adult T-Cell Leukemia | Phase 2 | 4 | 2016-04-22 | Adult T Cell Leukemia/Lymphoma | LENALIDOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | Phase 2 | 3 | 2019-04-03 | Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell | BORTEZOMIB, PANOBINOSTAT, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT01117441 | International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia | Phase 3 | 6,136 | Leukemia | ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, FLUDARABINE, IFOSFAMIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, THIOGUANINE, VINCRISTINE, VINDESINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06860269 | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia | Phase 2/3 | 1,200 | Acute Lymphoblastic Leukemia | BLINATUMOMAB, ISATUXIMAB, PONATINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00327678 | Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults | Phase 3 | 1,080 | Leukemia, Lymphocytic | IMATINIB MESYLATE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | Phase 3 | 1,023 | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, FLUDARABINE, IDARUBICIN, IMATINIB, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PREDNISOLONE, RITUXIMAB, VINCRISTINE, VINDESINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Phase 2/3 | 790 | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | BLINATUMOMAB, BORTEZOMIB, CALASPARGASE PEGOL, CLOFARABINE, CRISANTASPASE, CYCLOPHOSPHAMIDE, CYTARABINE, DASATINIB ANHYDROUS, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, ETOPOSIDE, IDARUBICIN, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PEGASPARGASE, PREDNISONE, RUXOLITINIB, VINCRISTINE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials68
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004963
GET https://conductscience.org/api/diseases/v1/MONDO_0004963/drugs?page=2